Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.

被引：0
|
作者：
Shevrin, Daniel H.
Symanowski, James Thomas
Shore, Neal D.
Lin, Daniel W.
Russell, David
Kral, Pavol
Song, Yi
El-Chaar, Nader N.
Karsh, Lawrence Ivan
机构：
[1] NorthShore Univ Hlth Syst, Glencoe, IL USA
[2] Atrium Hlth, Levine Canc Inst, Dept Biostat, Charlotte, NC USA
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Univ Washington, Inst Prostate Canc Res IPCR, Dept Urol, Seattle, WA USA
[5] Pfizer Inc, New York, NY USA
[6] IQVIA Inc, Bratislava, Slovakia
[7] Astellas Pharma Inc, Northbrook, IL USA
[8] Urol Ctr Colorado, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17085
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Determination of direct treatment costs of patients with metastatic and nonmetastatic castration-resistant (mCRPC, nmCRPC) and metastatic hormone-sensitive (mHSPC) prostate cancer in Colombia.
    Nino, Rafael
    Restrepo-Miranda, Diego
    Amezquita, Miguel Alberto
    Lancheros, Jeisson
    Corredor, Lina Maria
    Medina, Yudy
    Aguirre, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18838 - E18838
  • [2] Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.
    Lumen, Nicolaas
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    Thoret-Bauchet, Florence
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.
    Raval, Amit D.
    Chen, Guifang
    Korn, Matthew J.
    Bernthaler, Andreas
    Constantinovici, Niculae
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [4] Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document
    Lapini, Alberto
    Caffo, Orazio
    Pappagallo, Giovanni
    Iacovelli, Roberto
    D'Angelillo, Rolando Maria
    Vavassori, Vittorio
    Ceccarelli, Roberta
    Bracarda, Sergio
    Jereczek-Fossa, Barbara Alicja
    Da Pozzo, Luigi
    Conti, Giario Natale
    CANCERS, 2019, 11 (12)
  • [5] Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Lumen, Nicolaas
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    van den Berg, Erik
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Elahe A. Mostaghel
    Peter S. Nelson
    R. Bruce Montgomery
    Evan Y. Yu
    Heather H. Cheng
    Medical Oncology, 2016, 33
  • [8] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, R. Bruce
    Yu, Evan Y.
    Cheng, Heather H.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [9] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [10] The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Lumen, Nicolaas
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Spaeth, Dominique
    Antoni, Laurent
    Kiumper, Edwin
    Wapenaar, Robert
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345